Healthcare · NYSE/NASDAQ: REGN
REGENERON PHARMACEUTICALS, INC.
Biotechnology
Market Cap $57.78B
Verdict: High
Quality Scores
Multi-Bagger
82/100
Compounder Quality
93/100
Management Credibility
92/100
Governance
96/100
Cash Flow Quality
98/100
AI Summary
Regeneron Pharmaceuticals (REGN) has demonstrated exceptional growth over the last decade, evolving from a clinical-stage biotech into a highly profitable commercial powerhouse. The company experienced a massive revenue and profit peak in 2021-2022 due to COVID-19 related treatments (REGEN-COV), but has since successfully managed the transition back to long-term core therapeutic growth. Eylea and Dupixent remain dominant franchises, providing a heavy cushion of predictable cash flows to fuel a deep R&D pipeline. The balance sheet is fortress-like with zero long-term debt and massive liquid…
Top Opportunities
- Zero long-term debt profile
- OCF consistently above Net Income
- Massive blockbusters in Eylea and Dupixent
Top Risks
- Revenue concentration in few key molecules
- Patent cliff risks for Eylea
- Significant margin compression since 2020
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.